Dulaglutide
Dulaglutide (Trulicity): approved uses for type 2 diabetes, label warnings and what it is not approved for.
FDA-approved · Evidence grade A · Reviewed
Dulaglutide (Trulicity). GLP-1 receptor agonist.
AFDA-approved. Evidence grade A: approved, large human trials.
What is Dulaglutide?
Dulaglutide is a weekly GLP-1 injection used for type 2 diabetes.
Is Dulaglutide FDA-approved?
Approved as Trulicity for type 2 diabetes in adults and in children aged 10 and over. It is not approved for weight management.
What does the evidence show for Dulaglutide?
Large human trials, including cardiovascular outcome data in people with diabetes.
What are the known risks of Dulaglutide?
The label carries a boxed warning about thyroid C-cell tumors, based on rodent studies. It is not known whether the same happens in people. The most common side effects are nausea, vomiting, diarrhea, constipation and stomach pain. Labels for this class also warn about pancreatitis.
How is Dulaglutide measured?
Supplied as single-dose pens, so there is nothing to calculate.
Sources: Prime Therapeutics: GLP-1 pipeline update, August 2026; Managed Healthcare Executive: GLP-1 pills. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.